Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Jalpa Doshi

Leon Hess Professor of Internal Medicine

University of Pennsylvania

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United States Professors in Pharmacy Pharmacy professors in United States

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (9)

Jianjun Zhang

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

John Lin

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Carmen E. Guerra

University of Pennsylvania

UNITED STATES

View details

Benjamin Ricciardi

Associate Professor

University of Rochester

UNITED STATES

View details

William Chapin

University of Pennsylvania

UNITED STATES

View details

Joanna Rhodes

UNITED STATES

View details

Scott F Huntington

Yale University School of Medicine

UNITED STATES

View details

Caroline P. Thirukumaran

Associate Professor (tenured)

Northwestern University

UNITED STATES

View details

Ana Aparicio

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jalpa Doshi

Research Interests

Make your next move.

Explore related searches

Articles (20)

Reasons for and Outcomes of Medicare Part D Appeals for Denied GLP‐1 Receptor Agonist Claims

Insurance and Cost-Related Access Barriers to Specialty Oral Anticancer Medications for Blood Cancers in a Nationwide Sample of Medicare and Commercially Insured Patients

Specialty Oral Anticancer Prescription Fill Rates After Medicare Part D Cost-Sharing Changes in 2024.

Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancers

Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia

Reducing the Out-of-Pocket Costs of Disease-Modifying Therapies for Medicare Beneficiaries With Multiple Sclerosis

Reducing Medicare Part D Out-of-Pocket Costs for Specialty Oral Anticancer Drugs Under the Inflation Reduction Act: Highlighting the Benefits of Enrolling in the Medicare Prescription Payment Plan

Opioid Cap Laws and Opioid Prescriptions After Total Joint Replacements in Older Adults.

CAR-T for all? Barriers, facilitators, and interventions to commercial CAR T-cell therapy access.

Medicaid Coverage and Prior Authorization for Antiobesity Glucagon-Like Peptide-1 Receptor Agonists: A Cross-Sectional Study of State Policies.

Medicare Part D Coverage and Costs for Glucagon-Like Peptide-1 Receptor Agonists.

Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.

Inflation Reduction Act Provisions and Medicare Part D Out-of-Pocket Costs for Specialty Drugs.

Real-World Effectiveness of Long-Acting Injectable and Oral Antipsychotic Agents in US Medicare Patients with Schizophrenia.

Formulary Coverage of Brand-Name Adalimumab and Biosimilars Across Medicare Part D Plans

County-Level Factors Associated with Reversal of Insurer-Approved HIV Pre-Exposure Prophylaxis Prescriptions in the United States, 2018.

Clinician Specialty and HIV PrEP Prescription Reversals and Abandonments.

Real-Time Prescription Benefit Tool Adoption Among US Hospitals.

Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting.

Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis.

Collaborators (9)

Jianjun Zhang

John Lin

Carmen E. Guerra

Benjamin Ricciardi

William Chapin

Joanna Rhodes

Scott F Huntington

Caroline P. Thirukumaran

Ana Aparicio

Make your next move.